Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 2 Pituitary Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Sarcoma 1 Prostatic Neoplasms 1 Pituitary ACTH Hypersecretion 1 Pancreatic Neoplasms 1 Obesity 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Liposarcoma 1 Diabetes Mellitus, Type 2 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 69 Radiotherapy 50 Ifosfamide 48 Gemcitabine 43 Cyclophosphamide 36 pazopanib 29 Filgrastim 28 pembrolizumab 26 Docetaxel 26 Nivolumab 23 Surgical Procedures, Operative 21 Etoposide 21 Cisplatin 21 Trabectedin 19 Blood Specimen Collection 19 Carboplatin 15 Radiation 14 Magnetic Resonance Spectroscopy 14 Vincristine 13 Bevacizumab 13 anlotinib 12 Temozolomide 12 Peripheral Blood Stem Cell Transplantation 12 Ipilimumab 12 liposomal doxorubicin 11 apatinib 11 Radiosurgery 11 Neoadjuvant Therapy 11 Melphalan 11 Surveys and Questionnaires 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma × Rosiglitazone × Clear all

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡